Athos Therapeutics Secures FDA Green Light for Phase 2 Trial of Innovative ATH-063 in Ulcerative Colitis Battle
“Athos Therapeutics has obtained FDA clearance to launch a Phase 2 clinical trial for ATH-063, an AI-engineered oral small molecule aimed at treating moderate to severe ulcerative colitis in patients unresponsive to biologics. The drug targets inflammation and mucosal healing, building on successful Phase 1 outcomes that validated the company’s AI platform. This multi-center study … Read more